Promimic AB is a Sweden-based biomaterial company. The Company manufactures, markets and sells biomaterials for improved osseointegration (bone healing) to the companies in the markets for orthopedic and dental implants. The Company operates primarily in the United States, Europe, and South America, with current product applications in the dental, spine, total joint, extremities, and sports medicine implant markets.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
16/09/26	SEK 10.00	-0.99%	1,920
15/09/26	SEK 10.10	+1.00%	1,630
14/09/26	SEK 10.00	0.00%	1,503
11/09/26	SEK 10.00	0.00%	8,142
10/09/26	SEK 10.00	-1.96%	23,506

Delayed Quote Nasdaq Stockholm

More quotes

Market Closed - Nasdaq Stockholm 02:00:00 17/09/26 am AEST			5-day change	1st Jan Change
10.00 ^SEK	-0.99%		0.00%	-41.00%

20/08	Promimic AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
19/05	Promimic Q1 2026 operating loss at SEK 3.5 mln	RE

Market Cap	189M 19.22M 16.74M 15.8M 14.35M 26.9M 1.84B 27.02M 72.99M 937M 72.2M 70.6M 3.04B	P/E 2024	-33.7x	P/E 2025	-36.6x
Enterprise Value	168M 17.12M 14.91M 14.07M 12.79M 23.97M 1.64B 24.07M 65.02M 835M 64.32M 62.89M 2.71B	EV / Sales 2024	7.85x	EV / Sales 2025	6.74x
Free-Float	23.31%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Nasdaq Stockholm	PRO	Delayed
Deutsche Boerse AG	B0T	Delayed
Börse Stuttgart	B0T	Delayed
Boerse Muenchen	B0T	Real-time

20/08	Promimic AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
19/05	Promimic Q1 2026 operating loss at SEK 3.5 mln	RE
19/05	Promimic AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
16/04	Promimic nomination committee proposes new chairman	RE
24/02	Promimic Q4 net sales SEK 11.5 mln	RE
24/02	Promimic AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
20/11	Promimic Q3 sales of SEK 12.9 mln	RE
19/11	Promimic AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
22/08/25	Promimic AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
11/06/25	Promimic's CFO Heidi Bader makes a minor share purchase	FW
15/05/25	Promimic reports slightly lower operating loss	FW
15/05/25	Promimic Q1 Sales Increase 1.4% To 8.8 Msek	RE
15/05/25	Promimic AB Reports Earnings Results for the First Quarter Ended March 31, 2025	CI

Promimic AB Stock

Stocks

PRO

SE0017487242

Biotechnology & Medical Research

Valuation: Promimic AB

Chart: Promimic AB

Latest news: Promimic AB

Analysts' recommendations: Promimic AB

Press Releases: Promimic AB

Quotes and Performance

Price Extremes

Managers and Directors: Promimic AB

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

1 day	-0.99%
Current month	+9.89%
1 month	+1.52%
3 months	-3.85%
6 months	-15.25%
Current year	-41.00%

1 week	9.8	10.2
1 month	7.7	11.5
Current year	7.7	16.55
1 year	7.7	19.45
3 years	7.7	45
5 years	7.7	45
10 years	7.7	45

Manager	Title	Age	Since
Magnus Larsson CEO	Chief Executive Officer	63	18/01/2017
Per Gunnar Kjellin CTO	Chief Tech/Sci/R&D Officer	54	01/01/2004
Heidi Bader DFI	Director of Finance/CFO	45	01/01/2023

Director	Title	Age	Since
Tommy Karlsson BRD	Director/Board Member	80	01/01/2018
Helena Maria Brisby BRD	Director/Board Member	61	01/01/2021
Pia Renaudin BRD	Director/Board Member	59	01/01/2025

Date	Insider	Type	Main position	Quantity	% Market Cap.
11/10/24	Magnus Larsson	Exercice	Chief Executive Officer	16,000	0.0869%
11/10/24	Magnus Larsson	Exercice	Chief Executive Officer	160,000	0.8685%
11/10/24	Magnus Larsson	Sell	Chief Executive Officer	125,000	0.6785%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PROMIMIC AB	-0.99%	0.00%	-40.30%	-65.16%	19.24M
LONZA GROUP AG	+0.11%	+1.98%	-0.04%	+9.69%	46.18B
IQVIA HOLDINGS INC.	-1.12%	+3.54%	+42.71%	+25.84%	44.35B
REVOLUTION MEDICINES, INC.	-3.04%	-6.10%	+335.86%	+501.23%	42.21B
BEONE MEDICINES AG	-0.74%	+2.64%	+5.61%	+75.14%	40.19B
CELLTRION, INC.	-0.50%	-0.77%	+11.86%	+40.41%	29.83B
MEDPACE HOLDINGS, INC.	-0.46%	+5.00%	+23.00%	+118.70%	17.17B
ASCENDIS PHARMA A/S	-0.97%	-9.38%	-	-	15.7B
EUROFINS SCIENTIFIC SE	-0.57%	+7.78%	+21.76%	+38.08%	15.32B
ICON PUBLIC LIMITED COMPANY	-3.28%	-0.95%	-6.34%	-37.29%	13.09B
Average	-1.16%	+1.30%	+43.79%	+78.52%	26.41B
Weighted average by Cap.	-1.11%	+1.63%	+69.63%	+117.20%

	2024	2025
Net sales	48.91M 4.98M 4.33M 4.09M 3.72M 6.97M 477M 6.99M 18.9M 243M 18.69M 18.28M 787M	44.42M 4.52M 3.94M 3.71M 3.37M 6.33M 433M 6.35M 17.16M 220M 16.98M 16.6M 715M
Net income	-12.55M -1.28M -1.11M -1.05M -953K -1.79M -122M -1.79M -4.85M -62.27M -4.8M -4.69M -202M	-8.75M -891K -776K -732K -665K -1.25M -85.38M -1.25M -3.38M -43.44M -3.35M -3.27M -141M
Net Debt	-35.76M -3.64M -3.17M -2.99M -2.72M -5.09M -349M -5.11M -13.82M -177M -13.67M -13.36M -575M	-20.63M -2.1M -1.83M -1.73M -1.57M -2.94M -201M -2.95M -7.97M -102M -7.88M -7.71M -332M